Regulus Therapeutics (RGLS) Stock Price Up 5.6%
Shares of Regulus Therapeutics Inc (NASDAQ:RGLS) rose 5.6% on Tuesday . The stock traded as high as $0.20 and last traded at $0.19. Approximately 800,518 shares traded hands during mid-day trading, an increase of 3% from the average daily volume of 774,403 shares. The stock had previously closed at $0.18.
RGLS has been the topic of several recent analyst reports. B. Riley lowered their price target on Regulus Therapeutics from $1.00 to $0.50 and set a “neutral” rating on the stock in a report on Friday, July 6th. Wedbush reaffirmed a “hold” rating and issued a $1.00 price target on shares of Regulus Therapeutics in a report on Friday, August 10th. Wells Fargo & Co lowered their price target on Regulus Therapeutics from $1.50 to $1.00 and set a “market perform” rating on the stock in a report on Friday, July 6th. Zacks Investment Research raised Regulus Therapeutics from a “sell” rating to a “buy” rating and set a $0.25 price target on the stock in a report on Friday, July 13th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Regulus Therapeutics in a report on Friday, August 10th. Nine equities research analysts have rated the stock with a hold rating, The stock presently has an average rating of “Hold” and a consensus target price of $0.96.
The firm has a market cap of $20.42 million, a price-to-earnings ratio of -0.20 and a beta of 1.37.
An institutional investor recently bought a new position in Regulus Therapeutics stock. A.R.T. Advisors LLC acquired a new stake in shares of Regulus Therapeutics Inc (NASDAQ:RGLS) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 169,416 shares of the biopharmaceutical company’s stock, valued at approximately $121,000. A.R.T. Advisors LLC owned approximately 0.16% of Regulus Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 49.55% of the company’s stock.
Regulus Therapeutics Company Profile (NASDAQ:RGLS)
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
Featured Story: Intrinsic Value and Stock Selection
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.